

BDR Pharma launches cost effective drug for cancer patients

21 October 2020 | News

To provide access to breakthrough anti-cancer therapy at a cost-effective rate to Indian cancer patients



BDR Pharmaceutical has announced the launch of 4mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer. Lenvatinib is priced at Rs 1620 (4 mg) and Rs 2970 (10 mg) for a pack of 10 capsules.

Lenvatinib is a molecule used to provide breakthrough therapy treatment for cancer patients. The results of clinical trials conducted showed encouraging results with safety and efficacy on patients treated with aggressive tumors.

Dharmesh Shah, CMD, BDR Pharmaceuticals, Mumbai said, “2020 so far has been extraordinary on an operational front. By launching cost-effective therapy options, we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life-threatening diseases. The launch of Lenvatinib is a step forward in providing breakthrough treatment options at an affordable price, reducing the average cost of treatment drastically.”